Can Fite Biopharma Ltd
CANF0.646USD
-0.001-0.08%
Close 09/17, 16:00（ET）Quotes delayed by 15 min
2.56BMarket Cap
LossP/E TTM
More Details of Can Fite Biopharma Ltd Company
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Company Info
Ticker SymbolCANF
Company nameCan Fite Biopharma Ltd
IPO dateSep 22, 2005
CEODr. Pnina Fishman, Ph.D.
Number of employees5
Security typeOrdinary Share
Fiscal year-endSep 22
Address10 Bareket Street, Kiryat Matalon
CityPETAH TIKVA
Stock exchangeTel Aviv Stock Exchange
CountryIsrael
Postal code49170
Phone97239241114
Websitehttps://www.canfite.com/
Ticker SymbolCANF
IPO dateSep 22, 2005
CEODr. Pnina Fishman, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Sari Fishman, Ph.D.
Dr. Sari Fishman, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Yoseph Borenstein
Mr. Yoseph Borenstein
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
4.94%
Rhumbline Advisers Ltd. Partnership
0.37%
Abalone Asset Management Ltd.
0.15%
BNP Paribas Securities Corp. North America
0.11%
Two Sigma Investments, LP
0.10%
Other
94.33%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
4.94%
Rhumbline Advisers Ltd. Partnership
0.37%
Abalone Asset Management Ltd.
0.15%
BNP Paribas Securities Corp. North America
0.11%
Two Sigma Investments, LP
0.10%
Other
94.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
4.94%
Investment Advisor
0.65%
Research Firm
0.19%
Hedge Fund
0.10%
Other
94.11%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
29
155.14K
1.06%
-711.63K
2025Q1
30
155.14K
1.17%
-710.63K
2024Q4
28
154.43K
1.51%
-671.86K
2024Q3
26
794.33K
11.46%
+115.72K
2024Q2
26
667.93K
11.77%
+152.94K
2024Q1
24
517.69K
9.97%
+253.94K
2023Q4
29
283.94K
5.78%
+189.77K
2023Q3
28
67.77K
1.66%
-429.92K
2023Q2
28
54.74K
1.34%
-433.22K
2023Q1
31
368.56K
9.03%
+211.26K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rhumbline Advisers Ltd. Partnership
38.27K
0.29%
+11.39K
+42.37%
Mar 31, 2025
Abalone Asset Management Ltd.
23.81K
0.18%
-16.19K
-40.48%
Jun 30, 2024
BNP Paribas Securities Corp. North America
22.59K
0.17%
-2.60K
-10.32%
Mar 31, 2025
CAPTRUST Financial Advisors
10.63K
0.08%
+10.63K
--
Mar 31, 2025
Morgan Stanley & Co. LLC
23.21K
0.17%
-9.30K
-28.60%
Mar 31, 2025
MainStreet Advisors
3.00K
0.02%
--
--
Mar 31, 2025
Wells Fargo Advisors
2.70K
0.02%
+200.00
+8.00%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Date
Type
Ratio
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
